TriActiv approval
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash's 12-rep direct U.S. sales force will market the embolic protection system for saphenous vein graft (SVG) procedures following 510(k) clearance, announced March 24. TriActiv will compete with Boston Scientific's FilterWire and Medtronic's GuardWire in the estimated $100 mil.-$120 mil. marketfor SVG embolic protection. Kensey Nash is eyeing further indications and future-generation systems to expand the market (1"The Gray Sheet" March 21, 2005, p. 27)...